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ST-segment depression in lead V5 or lead V6. Stepwise multivar-
iate discriminant analysis did not select V5 or V6 as leads in which
ST-segment shift distinguished patients with acute LMCA ob-
struction from patients with acute obstruction of the left anterior
descending coronary artery (LAD). Therefore, we do not consider
ST-segment depression in leads V5 and V6 to be a characteristic
finding in “LMCA AMI patients.” The findings of our patients
indicated that lead aVR ST-segment elevation is not a mirror
image of ST-segment depression in leads V5 and V6.
Engelen et al. (4) reported that lead aVR ST-segment elevation
was observed in acute obstruction of the LAD proximal to the
major septal branch but not in acute LAD obstruction distal to the
major septal branch. They concluded that lead aVR ST-segment
elevation associated with proximal LAD obstruction was caused by
transmural ischemia of the basal part of the septum. Our findings
were completely in agreement with the findings by Engelen et al.
(4).
Our previous study (5) clearly demonstrated that isolated
diagonal branch occlusion caused ECG abnormalities in leads I
and aVL, while less frequently causing changes in the precordial
leads compared with those caused by acute LAD obstruction,
indicating that leads I and aVL represent myocardium perfused by
the diagonal branch. Acute LMCA obstruction causes ischemia in
myocardium perfused by the diagonal branch. Our finding that
ST-segment elevation in lead aVL was observed in high incidence
in LMCA AMI patients was completely in agreement with our
previous study (5). The ST-segment elevation in leads aVL and I
in LMCA AMI patients was caused by ischemia in myocardium
perfused by the diagonal branch associated with acute LMCA
obstruction.
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Cyclooxygenase-2 Inhibitors and
Cardiovascular Thromboembolic Events
In the recent perspective published by Bing and Lomnicka in the
Journal (1), several hypotheses were given for why cyclooxygenase-2
(COX-2) inhibitors may cause cardiovascular events. The investi-
gators even stated in their abstract that their report “confirms
evidence that selective nonsteroidal anti-inflammatory drugs
[NSAID] such as celecoxib can lead to thrombotic cardiovascular
events.” In fact, there are no data provided by Bing and Lomnicka
(1) nor from the clinical literature that clinical cardiovascular
events, defined as acute myocardial infarction, stroke and cardio-
vascular death, are increased owing to the COX-2 inhibitor,
celecoxib. Thus, I believe that their study is potentially misleading
to the readership of the Journal.
Using well-known basic pharmacology literature as a resource,
Bing and Lomnicka (1) stated that selective COX-2 inhibitors
attenuate the production of prostacylin, but do not alter throm-
boxane A2 levels and therefore may theoretically tip the balance in
favor of thrombosis. Thus, certain types of high-risk patients
treated with COX-2 inhibitors could be predisposed to increases in
cardiovascular events. To further support their hypothesis, how-
ever, they use the highly controversial post hoc analysis of data
from Mukherjee et al. (2), which suggested that the COX-2
inhibitors celecoxib and rofecoxib had a higher myocardial infarc-
tion event rate compared to an entirely unrelated, separate cohort
of generally healthy individuals in the placebo arm of four primary
prevention trials using aspirin (2). The sources of the pooled
analyses for the COX-2 inhibitors from the analysis of Mukherjee
et al. (2) derived from the Celecoxib Long-term Arthritis Safety
Study (CLASS) (3) and Vioxx Gastrointestinal Outcomes Re-
search (VIGOR) (4) trials using celecoxib and rofecoxib, respec-
tively, and two clinical trials that compared rofecoxib with a
nonselective NSAID, nabumetone. The CLASS and VIGOR
trials were conducted in approximately 8,000 arthritis patients each
and compared the gastrointestinal safety of the COX-2 inhibitors
versus the widely used NSAIDs, ibuprofen and diclofenac (in
CLASS) and naproxen (in VIGOR) for a median period of about
nine months in each trial.
A number of errors made by Mukherjee et al. (2) have now been
documented by numerous letters to the editor of JAMA in
December 2001. For example, patients in the CLASS trial who
were treated with low-dose aspirin (owing to prior cardiac or
cerebrovascular disorders) were compared to placebo patients who
had no known prior history of myocardial infarction (MI) from
four primary prevention trials evaluating the beneficial effects of
aspirin. The annual MI rates reported for celecoxib in CLASS and
rofecoxib in VIGOR by Mukherjee et al. for the entire group were
0.7% to 0.8% compared to a rate of 0.52% of MI observed in the
placebo group from the primary prevention trials. When the
patients who were nonusers of aspirin in the CLASS trial (about
3,100 patients) on celecoxib were assessed, the incidence of MI was
just 0.3%.
We recently reported on an extensive analysis of these throm-
bovascular events in the CLASS trial (5); that study showed no
evidence that high doses of celecoxib (400 mg twice daily)
increased the risk of acute MI, stroke, or venous thromboembolic
events compared to the conventional NSAIDs, ibuprofen or
diclofenac. This was true for the entire study population, both in
patients not taking aspirin and in patients taking aspirin. Similarly,
there have been no data from the premarketing clinical trials that
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show an increase in cardiovascular events on celecoxib versus
placebo nor celecoxib versus other nonselective NSAIDs (6) . One
would have to conclude, then, that there are no clinical outcome
data that support the hypothesis and statement of Bing and
Lomnicka (1) that the COX-2 inhibitor celecoxib causes cardio-
vascular events.
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REPLY
White, in his response to our study “Cyclooxygenase (COX-2)
Inhibitors and Cardiovascular Thromboembolic Events,” stated
“there are no clinical outcome data that support the hypothesis and
statement of Bing and Lomnicka that the COX-2 inhibitor
celecoxib causes cardiovascular events.” We have indeed no clinical
material of our own that demonstrates the effect of this selective
nonsteroidal anti-inflammatory compound (NSAID) on cardiac
events. But it was not our purpose to cite clinical material of our
own in support of the effects of celecoxib. Rather, we attempted to
demonstrate an experimental basis for the clinical trials by
Mukherjee et al. (1). We primarily wanted to stress the importance
of changes in prostanoids in heart muscle, specifically of throm-
boxane and prostacyclin. Prostacyclin is a vasodilator that prevents
cardiac arrhythmias and platelet aggregation; thromboxane, in
contrast, acts as a vasoconstrictor initiating ventricular arrhythmias
(2). Therefore, in the heart a decline in prostacyclin results in
coronary vasoconstriction, as does an increase in thromboxane. In
the kidney, a disproportionate decline in prostacyclin has even
more dire consequences (3), because both nonselective and selec-
tive NSAIDs cause acute renal failure (4–6). Changes in prosta-
noids in heart and kidney are related to the activity of cyclooxy-
genases (COX), which catalyze the conversion of arachidonic acid.
It was not our intention to present clinical evidence about the
effect of celecoxib. Rather, we wanted to stress reasons for the
possible relationship of NSAIDs to cardiac events. The decline in
prostacyclin following administration of NSAIDs and the resulting
deterioration in function confirm the predominant role of prosta-
noids in organ function.
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